Cowen & Co. Keeps Their Buy Rating on CytomX Therapeutics Inc

By Austin Angelo

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on CytomX Therapeutics Inc (NASDAQ: CTMX). The company’s shares opened today at $22.79.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.3% and a 51.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Currently, the analyst consensus on CytomX Therapeutics Inc is Strong Buy and the average price target is $40, representing a 75.5% upside.

In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $40 price target.

See today’s analyst top recommended stocks >>

Based on CytomX Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $621K. In comparison, last year the company had a GAAP net loss of $8.26 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics, Inc. operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer. The company was founded in September, 2010 and is headquartered in South San Francisco, CA.